LAB Quote, Financials, Valuation and Earnings

Ainos has a net margin of -63.81% compared to Standard BioTools's net margin of -15991.17%. Standard BioTools's return on equity of -26.52% beat Ainos's return on equity of -52.95%.

Standard BioTools has a consensus price target of $2.38, signalling upside risk potential of 121.96%. On the other hand Ainos has an analysts' consensus of -- which suggests that it could fall by --. Given that Standard BioTools has higher upside potential than Ainos, analysts believe Standard BioTools is more attractive than Ainos.

Standard BioTools has a beta of 1.804, which suggesting that the stock is 80.443% more volatile than S&P 500. In comparison Ainos has a beta of 2.137, suggesting its more volatile than the S&P 500 by 113.734%.

Standard BioTools has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ainos offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Standard BioTools pays -- of its earnings as a dividend. Ainos pays out -- of its earnings as a dividend.

Standard BioTools quarterly revenues are $40.8M, which are larger than Ainos quarterly revenues of $20.7K. Standard BioTools's net income of -$26M is lower than Ainos's net income of -$4.7M. Notably, Standard BioTools's price-to-earnings ratio is -- while Ainos's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Standard BioTools is 2.36x versus 56.16x for Ainos. Usually stocks with elevated PS ratios are considered overvalued.

Intelligent Bio Solutions has a net margin of -63.81% compared to Standard BioTools's net margin of -370.29%. Standard BioTools's return on equity of -26.52% beat Intelligent Bio Solutions's return on equity of -164.63%.

Standard BioTools has a consensus price target of $2.38, signalling upside risk potential of 121.96%. On the other hand Intelligent Bio Solutions has an analysts' consensus of -- which suggests that it could grow by 891.74%. Given that Intelligent Bio Solutions has higher upside potential than Standard BioTools, analysts believe Intelligent Bio Solutions is more attractive than Standard BioTools.

Standard BioTools has a beta of 1.804, which suggesting that the stock is 80.443% more volatile than S&P 500. In comparison Intelligent Bio Solutions has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Standard BioTools has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intelligent Bio Solutions offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Standard BioTools pays -- of its earnings as a dividend. Intelligent Bio Solutions pays out -- of its earnings as a dividend.

Standard BioTools quarterly revenues are $40.8M, which are larger than Intelligent Bio Solutions quarterly revenues of $607.5K. Standard BioTools's net income of -$26M is lower than Intelligent Bio Solutions's net income of -$2.2M. Notably, Standard BioTools's price-to-earnings ratio is -- while Intelligent Bio Solutions's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Standard BioTools is 2.36x versus 1.39x for Intelligent Bio Solutions. Usually stocks with elevated PS ratios are considered overvalued.

LENSAR has a net margin of -63.81% compared to Standard BioTools's net margin of -111.78%. Standard BioTools's return on equity of -26.52% beat LENSAR's return on equity of -134.77%.

Standard BioTools has a consensus price target of $2.38, signalling upside risk potential of 121.96%. On the other hand LENSAR has an analysts' consensus of $15.00 which suggests that it could grow by 7.76%. Given that Standard BioTools has higher upside potential than LENSAR, analysts believe Standard BioTools is more attractive than LENSAR.

Standard BioTools has a beta of 1.804, which suggesting that the stock is 80.443% more volatile than S&P 500. In comparison LENSAR has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Standard BioTools has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LENSAR offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Standard BioTools pays -- of its earnings as a dividend. LENSAR pays out -- of its earnings as a dividend.

Standard BioTools quarterly revenues are $40.8M, which are larger than LENSAR quarterly revenues of $16.7M. Standard BioTools's net income of -$26M is lower than LENSAR's net income of -$18.7M. Notably, Standard BioTools's price-to-earnings ratio is -- while LENSAR's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Standard BioTools is 2.36x versus 3.00x for LENSAR. Usually stocks with elevated PS ratios are considered overvalued.

Sight Sciences has a net margin of -63.81% compared to Standard BioTools's net margin of -62.11%. Standard BioTools's return on equity of -26.52% beat Sight Sciences's return on equity of -50.15%.

Standard BioTools has a consensus price target of $2.38, signalling upside risk potential of 121.96%. On the other hand Sight Sciences has an analysts' consensus of $3.62 which suggests that it could grow by 17.42%. Given that Standard BioTools has higher upside potential than Sight Sciences, analysts believe Standard BioTools is more attractive than Sight Sciences.

Standard BioTools has a beta of 1.804, which suggesting that the stock is 80.443% more volatile than S&P 500. In comparison Sight Sciences has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Standard BioTools has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sight Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Standard BioTools pays -- of its earnings as a dividend. Sight Sciences pays out -- of its earnings as a dividend.

Standard BioTools quarterly revenues are $40.8M, which are larger than Sight Sciences quarterly revenues of $19.1M. Standard BioTools's net income of -$26M is lower than Sight Sciences's net income of -$11.8M. Notably, Standard BioTools's price-to-earnings ratio is -- while Sight Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Standard BioTools is 2.36x versus 1.93x for Sight Sciences. Usually stocks with elevated PS ratios are considered overvalued.